Alto Neuroscience Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
ANRO$28.61+2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash Flows from Operating Activities: | ||
| Net loss | $(36,305) | $(27,710) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 373 | 342 |
| Loss on disposal of assets | 140 | — |
| Stock compensation expense | 2,891 | 1,763 |
| Change in fair value of preferred stock warrant liability | (525) | 369 |
| Non-cash lease expense | 280 | 263 |
| Non-cash interest expense related to term loan | 396 | — |
| Changes in operating assets and liabilities: | ||
| Other receivables | 325 | 1,158 |
| Prepaid expenses and other assets | (34) | (59) |
| Accounts payable | (632) | 1,006 |
| Accrued liabilities and other liabilities | (357) | 2,474 |
| Net cash used in operating activities | (33,448) | (20,394) |
| Cash Flows from Investing Activities: | ||
| Capital expenditures | (470) | (732) |
| Net cash used in investing activities | (470) | (732) |
| Cash Flows from Financing Activities: | ||
| Issuance of common stock | 181 | 43 |
| Issuance of convertible preferred stock | 70,000 | 34,262 |
| Share issue costs | (658) | (190) |
| Proceeds from issuance of term loan, net | — | 9,825 |
| Payment of debt issuance costs | — | (151) |
| Payment of deferred offering costs | (1,393) | — |
| Net cash provided by financing activities | 68,130 | 43,789 |
| Effect of exchange rate changes on cash & cash equivalents | (8) | (24) |
| Net increase in cash and cash equivalents | 34,204 | 22,639 |
| Cash at the beginning of the period | 48,344 | 25,705 |
| Cash at the end of the period | $82,548 | $48,344 |
| Supplemental Disclosure of Non-cash Activities | ||
| Allocation of proceeds to the K2 Warrant in connection with term loan issuance | $— | $209 |
| Deferred offering and share issue costs not yet paid | $916 | $— |
| Supplemental Disclosure of Cash Flow Information | ||
| Cash paid for interest | $912 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.